Ask most people what “evidence based medicine” means, and they picture something neutral, a drug tested rigorously until the data settles the question. What that picture leaves out is whose bodies produced the data in the first place. For most of modern pharmaceutical history, the answer was overwhelmingly men, and the consequences of that gap are still showing up in emergency rooms, pharmacies, and diagnostic delays today. This is not a fringe complaint. It is a documented, measurable feature of how medical science was built, and understanding it changes how you should read a prescription label, a symptom list, or even your own doctor’s confidence.

How Women Got Left Out Of The Data In The First Place

The exclusion was not accidental, and it did not start from malice. After the thalidomide disaster of the 1960s, when a drug prescribed to pregnant women caused severe birth defects, regulators moved to protect fetuses from any future drug testing catastrophe. In 1977, the FDA excluded women of childbearing potential from Phase I and early Phase II clinical research, and the guideline defined that category so broadly it covered any woman capable of becoming pregnant, regardless of contraceptive use, sexual orientation, or her partner’s fertility. The intention was caution. The effect was that an entire generation of drugs, from antidepressants to heart medication, was developed, dosed, and approved almost entirely on male physiology.

The policy held for sixteen years. The FDA reversed its 1977 guidance only in 1993, when the inclusion of women in clinical trials became part of federal law under the NIH Revitalization Act. That sounds like ancient history until you notice how recently the fallout has been getting corrected. The bias did not start at the clinical trial stage either. Fewer than 45 percent of animal studies on depression or anxiety include female subjects at all, meaning the exclusion runs all the way back to the mice and rats a drug meets years before it ever reaches a human trial.

The Sleeping Pill That Proved The Point

If one example makes the abstract problem concrete, it is zolpidem, sold under the brand name Ambien. Researchers analysed thousands of medical journal articles and found a clear drug dose gender gap across 86 different FDA approved medications, and zolpidem became the case study everyone remembers because the consequences were so measurable. Studies found women face five times the risk of driving impairment that men do at the standard 10 milligram dose, because the drug lingers longer in the female bloodstream, causing next morning drowsiness and significant cognitive impairment. The FDA responded in 2013 by halving the recommended dose for women, four decades after the drug family first reached the market. Zolpidem is simply the case where the harm was obvious enough, and specific enough, to force a correction. Researchers now believe similar undetected dosing gaps sit quietly inside dozens of other approved drugs that have never been re-examined with the same scrutiny.

Why Your Heart Attack Might Look Nothing Like The Textbook

Cardiology carries one of the starkest versions of this gap, and it even has a name. Yentl syndrome describes the pattern in which women are treated less aggressively in their first encounters with the healthcare system until they prove they are as sick as a male patient would be, a term coined in 1991 by cardiologist Dr Bernadine Healy. The core problem is definitional. Women experience higher odds of pain between the shoulder blades, nausea, vomiting, and shortness of breath during a heart attack, symptoms that fall outside the textbook image of crushing chest pain radiating down the left arm, and many current heart attack guidelines, including those around aspirin, were built on past studies that predominantly enrolled men. The real world cost of that gap is not abstract. Research from the UK found women are 50 percent more likely to be misdiagnosed following a heart attack, rising to almost 60 percent for some types, and mortality from ischemic heart disease runs twice as high in women under 50 compared to age matched men.

The Pain Gap Nobody Wants To Name

Pain treatment shows the same asymmetry from a different angle. Where cardiology under-recognises women’s symptoms, pain medicine has a long documented habit of not believing them at all. A landmark 2001 study identified how gender bias manifests in clinical pain management, describing women as more likely to have real physical pain reframed as a psychiatric issue. Endometriosis is the clearest modern casualty of that pattern. Despite affecting roughly one in ten women worldwide, the condition carries an average diagnostic delay of close to a decade in both the UK and the US, largely because severe period pain has historically been waved off as a normal, tolerable part of being a woman rather than investigated as a medical condition in its own right.

None of this means women’s bodies are more mysterious or more difficult to study than men’s. It means the default subject of medical research, for most of the twentieth century, was assumed to be male, and everyone else’s data was treated as a variation to correct for later rather than a baseline worth establishing from the start.

What Is Actually Changing

The picture is not static, and some of the correction is recent enough to still be underway. The 2022 Food and Drug Omnibus Reform Act introduced Diversity Action Plans, requiring clinical trial sponsors to build inclusion into their study design from the outset rather than treating it as an afterthought. Research funding bodies have expanded studies specifically focused on conditions that disproportionately affect women, and awareness of Yentl syndrome has started shifting emergency room triage protocols in parts of the world, even if the shift remains uneven and slow.

The most useful response to a gap this large, though, is not to wait for institutions to close it. It is to build a habit of understanding your own body’s baseline well enough to notice when something about it does not match the generic advice you have been handed. Track your own sleep, hormones, gut health, and stress as interconnected systems rather than isolated symptoms to treat one at a time. Pay attention to how pain tolerance, mood, and drug response shift across your own menstrual cycle, a variable clinical research spent decades treating as noise rather than signal. And if mood symptoms are something a doctor has been quick to label as anxiety or a personality trait rather than investigate, it is worth asking whether the pattern tracks with something hormonal or physiological that has simply never been named correctly.

Why The Data Gap Is Worth Knowing About At All

None of this is a call to distrust medicine. Modern pharmaceuticals and diagnostic tools save lives every single day, including women’s lives, on a massive scale. It is a call to understand the specific, documented shape of where the evidence base is thinner than it looks, so that a dismissed symptom gets a second opinion instead of an apology, and so that “the research doesn’t show that” gets met with the follow up question it deserves: research conducted on whom, exactly. Fifty years is not a long time in the history of medicine. It is, however, more than long enough to have built an entire evidence base around one half of the population and called it universal. Knowing where that gap sits is not paranoia. It is basic literacy about the system you rely on, and it is the first real step toward closing it.